NeuroVive Pharmaceutical and A1M Pharma to collaborate on mitochondrial medicine
Initial purpose is to utilise the companies’ complementary scientific platforms within the framework of ongoing research projects
NeuroVive Pharmaceutical, a leading mitochondrial medicine company, and A1M Pharma, which was founded by researchers at the University of Lund, Sweden, are initiating a research collaboration in mitochondrial medicine.
Initially, the purpose of the collaboration is to utilise the companies’ complementary scientific platforms within the framework of ongoing research projects. The companies will evaluate results achieved to date, then explore the potential for a closer collaboration focusing on bringing products to market in a time-efficient manner.
The costs related to the research collaboration will be covered by each company separately and within budgeted development projects. Both companies will retain exclusive ownership rights to existing registered intellectual property. However, any inventions arising from the collaboration will be owned jointly.
'I’m delighted to be able to announce this collaboration with A1M Pharma, which will give both parties access to a broader scientific platform in mitochondrial medicine,' said NeuroVive’s CEO Mikael Brönnegård. 'The companies’ adjacent research areas and strong R&D backgrounds, combined with their geographical proximity, will secure a smooth integration of existing research projects.'
'The collaboration will improve the potential for both parties to conduct leading research in mitochondrial medicine,' added A1M Pharma’s CEO Tomas Eriksson, although he stressed that his company would retain its focus on pre-eclampsia and renal failure.
